据界面,从阿斯利康公司获悉,其呼吸领域首款生物制剂凡舒卓®(英文商品名:Fasenra®,通用名:本瑞利珠单抗注射液)纳入中国国家医保目录。该产品主要治疗成人和12岁及以上青少年重度嗜酸粒细胞性哮喘(SEA)。
据界面,从阿斯利康公司获悉,其呼吸领域首款生物制剂凡舒卓®(英文商品名:Fasenra®,通用名:本瑞利珠单抗注射液)纳入中国国家医保目录。该产品主要治疗成人和12岁及以上青少年重度嗜酸粒细胞性哮喘(SEA)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.